Perioperative Heart Rate Control Therapeutics
1. Rapiblyk patent expiration
Treatment: A method of reducing the heart rate of a subject suffering from supraventricular tachycardia, wherein landiolol is administered parenterally at a constant dose of more than 20 mcg/kg/min for 2-20 hour...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10722516 | AOP HLTH US | NA |
Apr, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 22, 2029 |
Drugs and Companies using LANDIOLOL HYDROCHLORIDE ingredient
NCE-1 date: 22 November, 2028
Market Authorisation Date: 22 November, 2024
Dosage: POWDER
More Information on Dosage
RAPIBLYK family patents
